Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A Colao, University of Naples Federico II, Italy
Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly. However, some patients achieve inadequate control of their disease with conventional doses of octreotide LAR or lanreotide Autogel.
A Phase III, multicenter, randomised, parallel-group, three-arm, 24-week study is planned to assess the efficacy of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, as an alternative treatment for these patients. Data from this study is expected to be available sometime next year.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.